TRENDS IN CELL BIOLOGY, published by CELL PRESS, is a premier journal in the field of cell biology, recognized for its high-impact contributions since its inception in 1991. As a distinguished member of the Q1 quartile within its category, the journal holds an impressive Scopus ranking of #8 out of 285, placing it in the 97th percentile of the field, which underscores its reputation for excellence. The journal serves as an essential resource for researchers, professionals, and students who are engaged with groundbreaking advancements in biochemistry, genetics, and molecular biology. Although it is not open access, it provides critical insights into the latest trends, reviews, and advancements in cell biology, making it a crucial tool for anyone committed to understanding the complexities of cellular systems. With a focus on innovative and transformative research, TRENDS IN CELL BIOLOGY continues to shape the discourse in cell biology and enhance the scientific community's knowledge.

Genes & Diseases, published by KEAI PUBLISHING LTD, is a premier open-access journal dedicated to advancing the fields of genetics, biochemistry, and molecular biology. Established in 2014 and headquartered in Beijing, China, this journal has quickly risen to prominence, securing a place in the prestigious Q1 quartile in Biochemistry and Genetics (clinical), as well as Q2 in Cell Biology and Q1 in Molecular Biology as of 2023. With a commitment to disseminating cutting-edge research, Genes & Diseases serves as a critical platform for researchers, professionals, and students alike, ensuring that high-quality scientific work is openly accessible to the global community. The journal's exceptional impact is underscored by its selective Scopus rankings, which reflect its influence and relevance in key scientific domains, making it an essential resource for those exploring the intersections of genetics and disease pathology.

Journal of Cellular Biochemistry is a premier academic journal dedicated to advancing the field of biochemistry and cellular biology. Published by Wiley, this influential journal has a significant impact factor that underscores its relevance and authority within the scientific community. With its ISSN 0730-2312 and E-ISSN 1097-4644, the journal has been on the frontier of research since its inception in 1982, and is expected to continue publishing cutting-edge studies through 2024. As evidenced by its ranking in the 2023 Scopus Quartiles, it holds a rank of Q2 in Biochemistry and Q3 in both Cell and Molecular Biology, placing it among the top tiers of scientific journals in these disciplines. The Journal of Cellular Biochemistry serves as a vital resource for researchers, professionals, and students alike, providing a platform for the dissemination of innovative ideas and findings that shape our understanding of cellular processes and biochemical pathways. Though it does not currently offer Open Access options, its robust peer-review process ensures that each publication meets the highest academic standards, thus solidifying its esteemed position in the landscape of biochemical research.

FEBS LETTERS, published by Wiley, is a prestigious journal that has firmly established its place in the fields of biochemistry, biophysics, genetics, molecular biology, cell biology, and structural biology. With an esteemed history dating back to 1968, this journal continues to be a vital resource for researchers and professionals involved in the biological sciences. It boasts impressive quartile rankings, including Q1 statuses in several categories such as Biochemistry and Genetics, reflecting its high impact factor and significant contribution to scientific discourse. FEBS LETTERS provides a platform for innovative findings and critical reviews, fostering the exchange of knowledge and ideas within the scientific community. Although it operates under a subscription model, the journal ensures broad dissemination of groundbreaking research through its rigorous peer-review process. The vibrant discussions encouraged by articles published in FEBS LETTERS aim to inspire current and future generations of scientists to push the boundaries of biological understanding, making it an indispensable resource for anyone dedicated to advancing their knowledge in these dynamic fields.

FEBS Journal is a prestigious, peer-reviewed publication dedicated to advancing the field of biochemistry, cell biology, and molecular biology. Published by WILEY in the United Kingdom, this journal boasts an impressive impact factor and ranks in the top quartile (Q1) across multiple relevant categories, including Biochemistry, Cell Biology, and Molecular Biology, reflecting its significant contribution to scientific research. With an ISSN of 1742-464X and an E-ISSN of 1742-4658, the FEBS Journal publishes original research and comprehensive reviews that push the boundaries of knowledge and innovation in the biosciences. As a vital resource for researchers, professionals, and students alike, the journal offers Open Access options, ensuring that cutting-edge discoveries are accessible to a broad audience. With a publication history converging from 2005 to the present and a robust emphasis on high-quality scholarly work, the FEBS Journal remains an essential platform for the dissemination of significant findings and advancements in the life sciences.

Cell Death & Disease, published by SpringerNature, is a premier open-access journal dedicated to disseminating high-quality research on the mechanisms and implications of cell death, disease pathology, and therapeutic responses. Since its inception in 2010, the journal has quickly established itself within the top tier of academic publishing, achieving a notable impact factor and earning Q1 rankings in several critical categories including Cancer Research, Cell Biology, Cellular and Molecular Neuroscience, Immunology, and Medicine (miscellaneous). With its commitment to open access, Cell Death & Disease ensures that groundbreaking research is available to a global audience, fostering collaboration and advancing knowledge across disciplines. Residing at the forefront of crucial scientific discourse, this journal not only attracts submissions from leading researchers but also significantly influences the fields of molecular biology, immunology, and neurology. By bridging the gap between basic science and clinical applications, it provides vital insights for professionals, academicians, and students alike.

BIOLOGY OF THE CELL is a prominent academic journal published by Wiley, dedicated to advancing the field of cellular biology through the dissemination of innovative research and insights. With its ISSN (0248-4900) and E-ISSN (1768-322X), this journal has been a vital resource since its inception in 1981 and is set to continue its scholarly contributions until 2024. Positioned within the Q3 quartile in Cell Biology and Q2 in Medicine (miscellaneous) as of 2023, BIOLOGY OF THE CELL is recognized for its rigorous peer-review process and its commitment to high-quality publication in critical areas such as biochemistry, genetics, and molecular biology. Although the journal does not currently offer open access options, it remains accessible through the Wiley platform, ensuring that researchers, professionals, and students can benefit from its rich repository of knowledge. By linking fundamental cellular processes with broader medical implications, this journal serves as a critical platform for fostering dialogue and innovation in cellular research, making it an essential read for anyone engaged in the life sciences.

CYTOKINE & GROWTH FACTOR REVIEWS, published by Elsevier Science Ltd, serves as a premier platform for the dissemination of cutting-edge research in the fields of Biochemistry, Genetics and Molecular Biology, Endocrinology, and Immunology. With an impressive impact factor that places it in the Q1 category across multiple disciplines, the journal brings together high-quality reviews that critically evaluate recent advances in cytokine and growth factor biology. This ensures that researchers and professionals have access to valuable insights that enhance current knowledge and stimulate further investigation. Although it is not an open-access journal, its rigorous selection process and high ranking – including Rank #7 in Medicine: Endocrinology, Diabetes and Metabolism – underscore its significance within the scientific community. With its converged years of publication from 1996 to 2024, CYTOKINE & GROWTH FACTOR REVIEWS remains a crucial resource for students, researchers, and professionals alike, informing their work with comprehensive overviews of key topics in the dynamic interplay of growth factors and cytokines.

JOURNAL OF CELL SCIENCE, with ISSN 0021-9533 and E-ISSN 1477-9137, is a distinguished publication in the field of Cell Biology, released by COMPANY BIOLOGISTS LTD in the United Kingdom. Since its inception in 1966, this journal has served as a vital platform for disseminating cutting-edge research and reviews that significantly advance our understanding of cellular processes and innovations. Currently positioned in the Q1 category within the 2023 rankings, this journal is recognized for its high impact and quality, holding a notable Scopus rank of 120 out of 285 in the Cell Biology category, placing it within the 58th percentile. While not an open-access journal, it provides extensive access options for readers and institutions, ensuring that pivotal research is accessible to a wide audience. With converged publication years leading toward 2024, JOURNAL OF CELL SCIENCE continues to be an essential resource for researchers, professionals, and students alike, fostering a deeper understanding of the intricate workings of cell biology.

Advances in Cancer Biology-Metastasis is an emerging journal published by Elsevier, aimed at advancing our understanding of the complexities of cancer biology, with a specific focus on the mechanisms and pathways related to metastasis. With an E-ISSN of 2667-3940, this journal offers a platform for researchers, professionals, and students in the fields of Cancer Research and Cell Biology to disseminate innovative findings and discuss novel therapeutic approaches. Though currently classified in the Q4 quartile across both Cancer Research and Cell Biology categories, the journal aspires to enhance its impact through rigorous peer review and high-quality publication. Positioned to cover the years from 2021 to 2024, it seeks to bridge gaps in foundational knowledge and promote collaborative research efforts that could pivot the current understanding of cancer metastasis. Researchers are encouraged to take advantage of this platform to advocate for advancements in cancer biology, making significant contributions that can influence both academic and clinical practices.